Bleeding

Kaplan Survey: Law Schools Concerned about Class Diversity, Amid Affirmative Action Ban Fallout

Retrieved on: 
Monday, January 22, 2024
Education, Other Education, University, Student, Face, Bleeding, American Bar Association, News, School, Savoy Hotel, Silver, Supreme, Admission, Supreme court, Nursing

However, the silver lining lies in the promising trend of an increasingly diverse applicant pool, which presents an opportunity to mitigate any challenges they may face in achieving a representative student body," said Amit Schlesinger, executive director of legal and government programs , Kaplan.

Key Points: 
  • However, the silver lining lies in the promising trend of an increasingly diverse applicant pool, which presents an opportunity to mitigate any challenges they may face in achieving a representative student body," said Amit Schlesinger, executive director of legal and government programs , Kaplan.
  • “It’s unlikely this streak will continue given the Court’s decision, but law schools will likely do their best to stem the bleeding, while not violating the ruling.”
    To speak with a Kaplan law school admissions expert, contact [email protected] .
  • *Admissions officers from 85 of the nation’s 196 American Bar Association-accredited law schools were polled by e-mail and phone between August and November 2023.
  • Among the 85 law schools that participated are 22 of the top 50, as ranked by U.S. News & World Report.

Verseon Gains US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

Retrieved on: 
Wednesday, January 24, 2024
Risk, Stroke, Bleeding, Protease, Patent, Patient, Verseon, Splenic infarction, Anticoagulant, Cardiovascular disease, CSO, Pharmaceutical industry

FREMONT, Calif., Jan. 24, 2024 /PRNewswire/ -- Verseon is pleased to announce that the USPTO has issued a new patent, "Thrombin Inhibitors, Formulations, and Uses Thereof," that further extends intellectual property protection for Verseon's novel class of thrombin inhibitors. These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.

Key Points: 
  • These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.
  • Unlike current anticoagulants, Verseon's Precision Oral Anticoagulants (PROACs) covered by this patent exhibit a unique mechanism of action that does not increase the risk of bleeding yet prevents the formation of the dangerous blood clots behind heart attacks and strokes.
  • Because these compounds are also highly selective against other serine proteases, they are expected to cause fewer side effects.
  • "We are pleased by the USPTO's decision to grant additional patent protection for our PROACs," said Verseon's CSO David Kita.

Prytime Medical Names Dr. M. Chance Spalding New Chief Medical Officer

Retrieved on: 
Friday, January 19, 2024
Mount Carmel Health System, Death, Patient, Trauma, SAN, Resuscitation, University, Medicine, Surgery, Biomedical engineering, Doctor of Philosophy, Bleeding, Human, Surgeon, Ohio University, REBOA, Center of excellence, Acute kidney injury, Physician, Growth

SAN ANTONIO, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for minimally invasive, endovascular hemorrhage control and resuscitation, announced today the hiring of Chief Medical Officer, M. Chance Spalding, D.O., Ph.D., F.A.C.S.

Key Points: 
  • Additionally, he brings deep experience in clinical quality improvement, pREBOA-PRO™ programs, and teaching to lead Prytime Medical's global, clinical strategy.
  • SAN ANTONIO, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc, The REBOA Company™, the leading innovator and global provider of lifesaving REBOA products for minimally invasive, endovascular hemorrhage control and resuscitation, announced today the hiring of Chief Medical Officer, M. Chance Spalding, D.O., Ph.D., F.A.C.S.
  • "I'm excited to join Prytime Medical at this important time in its growth and evolution.
  • I've seen how partial REBOA using the pREBOA-PRO™ catheter gives me time to treat patients who are severely hypotensive," said Dr. Spalding.

Household Income and Health Insurance Among Factors in Decision to Withdraw Life Support After Hemorrhagic Stroke

Retrieved on: 
Thursday, January 18, 2024
Koto, Stroke, Death, Roger Hawkins (drummer), Patient, NYU Langone Health, Research, Medicaid, Bleeding, RN, BSN, Health, Intraparenchymal hemorrhage, Medicare, Rehabilitation, Religion, NYU, MSN, Neurosurgery, Coma, Neurology, Blood, Catholic Church, Brain, Intracerebral hemorrhage, Physician, Pharmaceutical industry

Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.

Key Points: 
  • Unlike ischemic stroke, which is caused by blocked blood vessels that can be cleared in many cases, hemorrhagic strokes are more often deadly.
  • By contrast, being Black and having private insurance were factors tied to a lower likelihood of life support being withdrawn.
  • Among hospitalized hemorrhagic stroke patients, Blacks made up 7% of those who had life support withdrawn but counted for 18% of those who maintained life support.
  • Similarly, while 37% had private health insurance, only 20% of those who decided to withdraw life support had private insurance.

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Retrieved on: 
Tuesday, January 16, 2024
Organ transplantation, RVV, Research, Nerve, Seizure, Survival, University, NAC, Injury, Inflammation, Neuroprotection, DRDC, Diazepam, Public, Infection, National security, Disorder, FDA, Therapy, Bleeding, Brain, Health Canada, Endocytosis, Pharmaceutical industry

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.

Key Points: 
  • TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.
  • The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.
  • DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
  • Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures.

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Regeneron Pharmaceuticals, Mouth ulcer, Patient, European, Conjunctivitis, Eosinophilia, Foot, Blepharitis, Keratitis, Walking, Aes, Skin, Food, Safety, Human, Inflammation, FDA, Physician, Bleeding, Atopic dermatitis, International development, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement. These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.

Key Points: 
  • These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.
  • “Having these data added for this difficult-to-treat population is important for physicians looking for tools to treat these patients and reinforces the already well-established efficacy and safety of Dupixent in atopic dermatitis overall.”
    The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial.
  • In the trial, patients received Dupixent (n=67) every two weeks (adults 300 mg, adolescents 200 mg or 300 mg based on body weight) or placebo (n=66).
  • Most common adverse events (AEs) observed with Dupixent (≥1%) in atopic dermatitis include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye and eosinophilia.

Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, Entrepreneurship, Patient, Hospital, Temperature, Anaphylaxis, Food, Multiple myeloma, Chromosome, Human, Melphalan, Safety, Bone marrow, Boxed warning, Bleeding, Aplastic anemia, Infection, Abbreviated New Drug Application, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug Administration.
  • Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
  • Avenacy’s Melphalan Hydrochloride for Injection is available in a kit containing a 50mg vial of lyophilized active ingredient and a 10mL vial of sterile diluent for admixture.
  • “Melphalan Hydrochloride for Injection will feature our proprietary product packaging and labeling, supporting our commitment to championing reliability, safety, and convenience for our customers.

In NCLA Amicus Win, Supreme Court Will Hear Case Against NLRB’s Odd Prelim Injunction Standard

Retrieved on: 
Friday, January 12, 2024
Starbucks, Sixth, Commerce, Fifth, Supreme, Government, Court, Water, Judge, NLRB, Supreme court, Bleeding, National Labor Relations Board, NCLA, McKinney, Texas

NLRB used a preliminary injunction it obtained in federal district court without ever establishing that Starbucks likely broke the law.

Key Points: 
  • NLRB used a preliminary injunction it obtained in federal district court without ever establishing that Starbucks likely broke the law.
  • NCLA filed an amicus curiae brief in Starbucks Corp. v. McKinney, asking the Justices to grant cert, reverse the Sixth Circuit, and overturn NLRB’s special injunction standard.
  • The Supreme Court has clarified, in many different contexts, that federal courts may not issue preliminary injunctions unless the party seeking the P.I.
  • Now, the Supreme Court has an opportunity to end this abusive practice nationwide.”
    “NLRB’s sui generis preliminary injunction standard is a judge-made departure from the norm.

AirLift Texas Celebrates Grand Opening of New Fixed Wing Base

Retrieved on: 
Thursday, January 11, 2024
Weather, Spirometer, Death, Patient, Commerce, Shock (mechanics), Atmosphere of Earth, Insurance, Bleeding, Air Methods, Risk, Aircraft, Travel, Safety, Obstetrics, Nursing care plan, Blood

NEW BRAUNFELS, TEXAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The AirLift Texas team was overjoyed to be joined on Tuesday by local first responders, hospital partners, the Greater New Braunfels Chamber of Commerce and Joyce Yannuzzi, District Director for Texas State Senator Donna Campbell, M.D., in the official ribbon-cutting ceremony to celebrate the grand opening of their new fixed wing base—AirLift 10.

Key Points: 
  • NEW BRAUNFELS, TEXAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The AirLift Texas team was overjoyed to be joined on Tuesday by local first responders, hospital partners, the Greater New Braunfels Chamber of Commerce and Joyce Yannuzzi, District Director for Texas State Senator Donna Campbell, M.D., in the official ribbon-cutting ceremony to celebrate the grand opening of their new fixed wing base—AirLift 10.
  • “I know she’ll have patients that will benefit greatly from having AirLift Texas in this area, so on her behalf and on behalf of her office, welcome to New Braunfels.
  • Centrally located in Texas, this air medical asset adds to the current AirLift rotor wing ecosystem in Waco and Weslaco and supports sister base AirLIFE in Uvalde.
  • Because it’s a fixed wing aircraft, the AirLift 10 team can serve patients needing to travel further distances for definitive care.

Student Organizations Join Forces to Encourage Donations During National Blood Donor Month

Retrieved on: 
Wednesday, January 10, 2024
Student, Blood transfusion, Patient, Next Generation Science Standards, Trauma, AACN, Vein, Hospital, Partnership, Science, Bleeding, AAMC, HOSA (organization), ABC, Cancer, American Dental Association, Food, Plasma, Bone marrow, Transplant, HOSA, Mathematics, ADEA, Organization, Language arts, Professional, The arts, Education, Motivation, Blood, Medical device

This National Blood Donor Month, we encourage educators, students, and all eligible individuals to start the New Year by answering the call to make a difference through blood donation," said Kate Fry, CEO of America’s Blood Centers.

Key Points: 
  • This National Blood Donor Month, we encourage educators, students, and all eligible individuals to start the New Year by answering the call to make a difference through blood donation," said Kate Fry, CEO of America’s Blood Centers.
  • "National Blood Donor Month brings a time to recognize the tremendous impact made through the HOSA-Future Health Professionals and America’s Blood Centers partnership and bring awareness to the ongoing need for support.
  • One of the ways we can show our appreciation and gratitude is by supporting National Blood Donor Month, which aims to raise awareness of the need for blood donations and to encourage people to donate blood regularly,” said Mandy Nau, Executive Director of Health Professions Week.
  • This month continues to be celebrated each year to thank America's blood donors and encourage more people to donate blood.